These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 25398489)

  • 21. Therapeutic implications of IL-17A blockade in psoriasis.
    Puig L; Carrascosa JM
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
    Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
    Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-17 and innate immunity in infections and chronic inflammation.
    Isailovic N; Daigo K; Mantovani A; Selmi C
    J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis.
    Bauer E; Lucier J; Furst DE
    Expert Opin Biol Ther; 2015 Jun; 15(6):883-93. PubMed ID: 25985813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.
    Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F
    J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
    Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
    J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
    Fragoulis GE; Siebert S; McInnes IB
    Annu Rev Med; 2016; 67():337-53. PubMed ID: 26565676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasis: rationale for targeting interleukin-17.
    Girolomoni G; Mrowietz U; Paul C
    Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting IL-17 in autoimmunity and inflammation.
    Kim BS; Park YJ; Chung Y
    Arch Pharm Res; 2016 Nov; 39(11):1537-1547. PubMed ID: 27576555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
    Blauvelt A; Chiricozzi A
    Clin Rev Allergy Immunol; 2018 Dec; 55(3):379-390. PubMed ID: 30109481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
    Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
    Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
    Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasis and other Th17-mediated skin diseases.
    Tokura Y; Mori T; Hino R
    J UOEH; 2010 Dec; 32(4):317-28. PubMed ID: 21226422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
    Guttman-Yassky E; Krueger JG
    Curr Opin Immunol; 2017 Oct; 48():68-73. PubMed ID: 28869867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.
    Sakkas LI; Bogdanos DP
    Autoimmun Rev; 2017 Jan; 16(1):10-15. PubMed ID: 27666819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
    Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
    Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th17 cells: a new therapeutic target in inflammatory dermatoses.
    Asarch A; Barak O; Loo DS; Gottlieb AB
    J Dermatolog Treat; 2008; 19(6):318-26. PubMed ID: 18626814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?
    Lubberts E
    Cytokine; 2008 Feb; 41(2):84-91. PubMed ID: 18039580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.